- Rentschler Biopharma’s management and business development team will be present at BioProcess International Asia in Kyoto, Japan, from October 20-22, 2025.
- The company plans to showcase the Rentschler Expression Platform, designed to accelerate cell line development timelines, and Rentschler Development Services, which offers tailored solutions.
LAUPHEIM, Germany, Oct. 06, 2025 — Rentschler Biopharma SE, a prominent global contract development and manufacturing organization (CDMO) for biopharmaceuticals, is emphasizing its adaptable and optimized solutions for the development and manufacturing of various biologics for clients in Japan and South Korea. As part of its continuous commitment and strategic focus on expanding its services in the region, Rentschler Biopharma will participate in BioProcess International Asia in Kyoto. The company also intends to connect with existing and potential partners to explore collaborative opportunities and gain insights into their evolving needs.
Given their robust and expanding biopharma sectors, Japan and South Korea are vital markets for biopharmaceutical development. Rentschler Biopharma has been actively involved in the region for several years, serving a diverse clientele with the support of its established regional partner, Summit Pharmaceuticals International (SPI).
“At Rentschler Biopharma, we greatly appreciate the trust our client partners in Japan and South Korea have placed in us. We are eager to strengthen these relationships and forge new strategic partnerships through ongoing collaboration. We share our clients’ dedication to delivering innovative, high-quality treatments to patients worldwide swiftly and efficiently,” stated Benedikt von Braunmühl, CEO of Rentschler Biopharma. He added, “We aim to provide our clients with the reliability necessary to progress their projects from initial concept to market approval. By consistently pushing the boundaries of biotherapeutic development and manufacturing, we are advancing medicine to save lives.”
During a roadshow in Japan, Rentschler Biopharma will offer insights into how the company is positioned to provide new and expedited manufacturing capabilities, leveraging its in-depth understanding of the complete drug substance development and manufacturing spectrum. The company possesses extensive expertise, specialized knowledge, and advanced technology, enabling comprehensive client support from cell line development, upstream and downstream development, and GMP manufacturing to analytical testing, product characterization, and regulatory affairs.
“Our allows us to customize our services to meet our clients’ specific project requirements, from expedited development options to handling complex, molecule-specific projects. Furthermore, with our facilities in Germany, at the heart of Europe, and in the Greater Boston area, the most important biopharma hub in the United States, we manufacture clients’ products close to their target markets, significantly accelerating the time to clinic and market reliably and seamlessly,” said Dr. Patrick Meyer, Global Head of Business Development at Rentschler Biopharma.
To tailor its process development and manufacturing services to Japanese clients, Rentschler Biopharma is working closely with SPI as its established partner. This collaboration ensures that clients benefit from smooth communication, localized regulatory insights, and culturally sensitive project management. Katsuya Okuyama, President & CEO of SPI, commented: “Together with Rentschler Biopharma, we are honored to collaborate with biopharmaceutical companies in Japan. Our companies share the goal of enriching lives and the world through the improvement of health and well-being. We are looking forward to meeting our valued partners on the roadshow through Kyoto, Osaka and Tokyo.”
|
About Rentschler Biopharma SE
Rentschler Biopharma is a leading contract development and manufacturing organization (CDMO) exclusively dedicated to client projects. The company provides process development and manufacturing of biopharmaceuticals, along with related consulting, project management, and regulatory support. Rentschler Biopharma’s long-standing experience and excellence as a solution partner for its clients demonstrate its high quality. A sophisticated quality management system, a well-established operational excellence philosophy, and advanced technologies ensure product quality and productivity at every stage of development and manufacturing. Rentschler Biopharma is a family-owned company with approximately 1,400 employees, headquartered in Laupheim, Germany, and with operations in Milford, MA, USA. In 2024, the company joined the United Nations Global Compact, underscoring Rentschler Biopharma’s commitment to sustainability. For more information about the company, please visit . Follow Rentschler Biopharma on .
Contact:
Rentschler Biopharma SE
Dr. Latika Bhonsle-Deeng
Global Head of Communications
Phone: +49-7392-701-467
Media inquiries:
| MC Services AG Eva Bauer Phone: +49-89-210228-0 |
U.S. Laurie Doyle Phone: +1-339-832-0752 |
A photo accompanying this announcement is available at
“`